{"id":"nct:NCT04951323","kind":"trial","title":"Impact of the Immune System on Response to Anti-Coronavirus Disease 19 (COVID-19) Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo)","authors":["University of Liege"],"author_count":1,"year":2021,"published":"2021-07-06","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT04951323","source_url":"https://clinicaltrials.gov/study/NCT04951323","archive_url":"https://space-kitty.com/papers/nct:NCT04951323","updated":"2022-05-18","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"The present study is a prospective phase IV study. All participants will receive the anti-Coronavirus Disease 2019 (COVID-19) Vaccine (messenger Ribonucleic acid-based vaccine, BNT162b2 or Comirnaty®, commercialized by Pfizer-BioNTech) being authorized in the European Union since December 2020. The vaccine is administered intramuscularly after dilution as a series of two doses at least 21 days apart.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Coronavirus Disease 2019 (Covid19)","Hematopoietic Neoplasms"],"details":{"acronym":null,"status":"UNKNOWN","phase":"PHASE3","study_type":"INTERVENTIONAL","enrollment":50,"sponsor":"University of Liege","conditions":["Coronavirus Disease 2019 (Covid19)","Hematopoietic Neoplasms"],"interventions":["DRUG: anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)"],"start_date":"2021-03-22","start_date_type":"ACTUAL","primary_completion_date":"2022-12-01","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"mrna-cancer-vaccines","name":"mRNA Therapeutics & Cancer Vaccines","domain_slug":"medicine"}],"cited_in_dossiers":[]}